ERASERASHealthcare · Biotechnology

ERAS Stock Forecast: Erasca, Inc. Price Predictions for 2026-2027

Last close, 17 Nov 2026
$14
−8.07% on the day

The 10 Wall Street analysts covering Erasca, Inc. hold a median 12-month price target of $23 — +65.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 16 Nov 2026 — in the lower half.

Market cap
$4.9B
Ticker Nerd rank
48/ 100
Median analyst target
$23
Analysts covering
10
Revenue$0.0
Operating income−$47.6M
Net income−$44.1M
Free cash flow−$27.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.3%
1M
+3.7%
YTD
+273.4%
1Y
+384.0%
From 52W high
−38.2%
From 52W low
+403.3%
$3
$22
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ERAS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Erasca, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 16 Nov 2026
48/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
92
Value
90
Quality
63
Accruals
59
Issuance
41
Revisions
33
Volatility
32
Growth
27
Size
22

Momentum (92): The shares have been drifting up relative to others.

Growth (27): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (22): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ERAS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ERAS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Jan 26Apr 26Jul 26Oct 26ERASHigh $35Median $23Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
8 Buy2 Hold0 Sell
Low $20Median $23High $35

The green dot is the last close — the median target sits +65.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
17 Nov 2026Leerink PartnersInitiatesOutperform$35
14 Aug 2026B of A SecuritiesMaintainsNeutral$18 → $20
13 Aug 2026GuggenheimMaintainsBuy$20 → $21
12 Aug 2026HC Wainwright & Co.MaintainsBuy$18 → $22
20 July 2026Morgan StanleyMaintainsEqual-Weight$12 → $21
20 July 2026Morgan StanleyMaintainsEqual-Weight—
14 July 2026B of A SecuritiesMaintainsNeutral$16 → $18
14 July 2026B of A SecuritiesMaintainsNeutral—
4 June 2026B of A SecuritiesUpgradeNeutral$9.00 → $16
4 June 2026B of A SecuritiesUpgradeNeutral—
12 May 2026MizuhoMaintainsOutperform—
27 Apr 2026StifelMaintainsBuy—
18 Mar 2026JP MorganMaintainsOverweight—
16 Mar 2026GuggenheimMaintainsBuy—
13 Mar 2026HC Wainwright & Co.MaintainsBuy—
13 Mar 2026MizuhoMaintainsOutperform—
13 Mar 2026Piper SandlerMaintainsOverweight—
6 Mar 2026Clear StreetMaintainsBuy—
26 Jan 2026HC Wainwright & Co.MaintainsBuy—
16 Jan 2026Piper SandlerMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ERAS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ERAS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 17 Nov 2026, Erasca, Inc. returned +384.0% against +11.2% for the S&P 500, dividends included.

ERAS vs S&P 500, last 12 monthsTotal return, rebased to 100
0200400600800Jan 26Apr 26Jul 26Oct 26ERASS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ERAS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
3
Analysts cutting
6
Fundamentals

Erasca, Inc. (ERAS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−31.6×

Cheaper than 98% of US stocks

Price / sales
—
Price / book
5.3×

Cheaper than 15% of US stocks

EV / EBITDA
−24.5×

Cheaper than 92% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 33% of US stocks

Net margin
0.0%

Higher than 29% of US stocks

Returns & dividend
Return on equity
−48.7%

Higher than 22% of US stocks

Return on assets
−15.6%

Higher than 22% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Erasca, Inc. (ERAS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Erasca, Inc. has a market value of $4.9B and an enterprise value of $4.3B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$287.2M.

  • Diluted earnings per share, trailing twelve months: −$0.95.

  • Free cash flow in the twelve months to 30 June 2026: −$252.1M.

  • Shares outstanding: 312.6M.

  • Trailing P/E: −31.6×; forward P/E: −18.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Erasca, Inc. employs 103 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

ERAS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ERASErasca, Inc.$4.9B48
MANEVeradermics, Inc.$5.3B5
PTCTPTC Therapeutics, Inc.$5.1B64
SRRKScholar Rock Holding Corp.$5.4B47
DNTHDianthus Therapeutics, Inc.$4.9B77
COGTCogent Biosciences, Inc.$4.7B33
EWTXEdgewise Therapeutics, Inc.$4.7B69

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Erasca, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ERAS news & analysis

Erasca Reports Third Quarter 2026 Business Updates and Financial Results

GlobeNewsWire · 12 Nov 2026positive

Erasca reported third-quarter 2026 results and business updates, including FDA Fast Track designation for ERAS-0015 in metastatic pancreatic adenocarcinoma and progress toward three potentially registration-enabling trials in pancreatic and lung cancers. The company reported $948 million in cash, cash equivalents, and marketable securities at September 30, 2026, and outlined expected data presentations and updates in 2026 and 2027.

Why it matters — The update highlights regulatory and clinical-development milestones, upcoming data disclosures, and the company’s reported cash position.

Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015

GlobeNewsWire · 4 Nov 2026positive

Tango Therapeutics and Erasca announced that a Phase 1/2 study of vopimetostat with ERAS-0015 is open for enrollment. The study will evaluate the combination in patients with MTAP-deleted pancreatic ductal adenocarcinoma and MTAP-deleted/RAS-mutant non-small cell lung cancer.

Why it matters — The study advances evaluation of Erasca’s pan-RAS molecular glue ERAS-0015 in combination with a PRMT5 inhibitor in two cancer populations.

Erasca to Present at Upcoming Conferences in November

GlobeNewsWire · 3 Nov 2026neutral

Erasca announced that management will participate in the Guggenheim, Stifel and Jefferies healthcare conferences in November 2026, including fireside chats and one-on-one investor meetings. Live audio webcasts will be available at Erasca.com/events.

Why it matters — The appearances give ERAS watchers scheduled opportunities to hear from management and access the company’s conference presentations.

FAQ

Frequently asked questions about ERAS stock

What is the ERAS stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Erasca, Inc. have a median 12-month price target of $23, with estimates ranging from $20 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ERAS stock a buy right now?

Of the 10 analysts covering Erasca, Inc., 8 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Erasca, Inc. 48 out of 100 across roughly 4,600 US stocks as at 16 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ERAS?

As at 16 Nov 2026, Erasca, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (92 of 100).

Will ERAS stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +65.6% from the last close, and Ticker Nerd's factor model ranks Erasca, Inc. 48 out of 100 as at 16 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ERAS stock forecast for 2030?

No analyst covering Erasca, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ERAS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $35 over the next 12 months.

How has ERAS stock performed over the past year?

Erasca, Inc. returned +384.0% over the 12 months to 17 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Erasca, Inc. do?

Erasca Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for cancers driven by the RAS/MAPK signaling pathway.

What is the latest news on ERAS?

The most recent item we track (GlobeNewsWire, 17 Nov 2026): "Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat". Erasca entered into a clinical collaboration with Bristol Myers Squibb to evaluate ERAS-0015 alongside the PRMT5 inhibitor navlimetostat in a Phase 1/2 trial for MTAP-deleted pancreatic cancer.

Company

About Erasca, Inc.

Erasca Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for cancers driven by the RAS/MAPK signaling pathway. The company’s current portfolio centers on targeted drug candidates designed to address difficult-to-treat solid tumors through biomarker-guided approaches. Its development programs span multiple mechanisms, including agents that act on key nodes within the RAS/MAPK pathway and therapies intended to overcome resistance pathways in cancer cells. Erasca’s work is concentrated on precision medicine in oncology, with an emphasis on selecting patient populations most likely to benefit from its investigational treatments. Based in San Diego, California, Erasca plays a role in the biotechnology market as a research-driven company advancing experimental cancer therapies through clinical development and collaborative studies.

CEO Dr. Jonathan E. Lim M.D. · 103 employees · United States · https://www.erasca.com